This page has only limited features, please log in for full access.

Prof. Noemie Jourde-Chiche
Aix-Marseille University, C2VN, INRAE 1260, INSERM 1263 ; Centre de Néphrologie et Transplantation Rénale, Hôpital de la Conception, AP-HM, Marseille, France

Basic Info


Research Keywords & Expertise

0 Biomarker Discovery
0 Clinical nephrology
0 Endothelial dysfunction
0 Lupus nephritis
0 Clinical and translational research

Fingerprints

Lupus nephritis
Endothelial dysfunction
Therapeutic trials

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Correspondence
Published: 25 August 2021 in Journal Français d'Ophtalmologie
Reads 0
Downloads 0
ACS Style

P. Bastelica; M. Labetoulle; N. Noel; E. Barreau; F. Matonti; N. Jourde Chiche; A. Rousseau; J. Benichou. Atteintes rétiniennes au cours de la vascularite urticarienne hypocomplémentémique (syndrome de McDuffie) : à propos de deux cas. Journal Français d'Ophtalmologie 2021, 1 .

AMA Style

P. Bastelica, M. Labetoulle, N. Noel, E. Barreau, F. Matonti, N. Jourde Chiche, A. Rousseau, J. Benichou. Atteintes rétiniennes au cours de la vascularite urticarienne hypocomplémentémique (syndrome de McDuffie) : à propos de deux cas. Journal Français d'Ophtalmologie. 2021; ():1.

Chicago/Turabian Style

P. Bastelica; M. Labetoulle; N. Noel; E. Barreau; F. Matonti; N. Jourde Chiche; A. Rousseau; J. Benichou. 2021. "Atteintes rétiniennes au cours de la vascularite urticarienne hypocomplémentémique (syndrome de McDuffie) : à propos de deux cas." Journal Français d'Ophtalmologie , no. : 1.

Preprint content
Published: 08 June 2021
Reads 0
Downloads 0

Objective Patients with systemic lupus erythematosus (SLE) display symptoms that are not always related to disease activity and may distort clinical trial results. Recently, a clinical categorization based on the presence of type 1 (inflammatory manifestations) and/or type 2 (widespread pain, fatigue, depression) symptoms has been proposed in SLE. Our aim was to develop a type 2 score derived from the Short-Form health survey (SF-36) to categorize SLE patients and to compare immunological and transcriptomic profiles between groups. Methods Seventeen items from the SF-36 were selected to build a type 2 score for 50 SLE patients (100 visits; LUPUCE cohort) and the SLEDAI was used to define type 1 symptoms. Patients were categorized in four groups: minimal (no symptoms), type 1, type 2 and mixed (both type 1 and type 2 symptoms). Clinical, immunological and transcriptomic profiles were compared between the groups. Results Type 2 scores ranged from 0 to 31, with a cut-off value of 14 (75th percentile). The sample categorization was: minimal in 39%, type 1 in 37%, type 2 in 9% and mixed in 15%. Type 2 patients were older than minimal patients and had a longer disease duration than type 1 and mixed patients. Immunological data and modular interferon signatures did not differ between the groups. Conclusion Patients with SLE can be categorized into four clinical groups using the SLEDAI score and our SF-36-derived type 2 score. This categorization is non-redundant with immunological or transcriptomic profiles and could prove useful to stratify patients in clinical trials.

ACS Style

Robin Arcani; Elisabeth Jouve; Laurent Chiche; Noemie Jourde-Chiche. Categorization of Patients With Systemic Lupus Erythematosus Using Disease Activity, Patient-Reported Outcomes and Transcriptomic Signatures. 2021, 1 .

AMA Style

Robin Arcani, Elisabeth Jouve, Laurent Chiche, Noemie Jourde-Chiche. Categorization of Patients With Systemic Lupus Erythematosus Using Disease Activity, Patient-Reported Outcomes and Transcriptomic Signatures. . 2021; ():1.

Chicago/Turabian Style

Robin Arcani; Elisabeth Jouve; Laurent Chiche; Noemie Jourde-Chiche. 2021. "Categorization of Patients With Systemic Lupus Erythematosus Using Disease Activity, Patient-Reported Outcomes and Transcriptomic Signatures." , no. : 1.

Preprint content
Published: 18 May 2021
Reads 0
Downloads 0

Background . Hypocomplementemic urticarial vasculitis (HUV) is a rare systemic vasculitis. We aimed to describe the kidney involvement of HUV in a multicenter national cohort with an extended follow-up. Methods. All patients with HUV (international Schwartz criteria) with a biopsy-proven kidney involvement, identified through a survey of the French Vasculitis Study Group, were included. A systematic literature review on kidney involvement of HUV was performed. Results. Twelve patients were included, among whom 8 had positive anti-C1q antibodies. All presented with proteinuria, from mild to nephrotic, and 8 displayed acute kidney injury (AKI), requiring temporary haemodialysis in 2. Kidney biopsy showed membrano-proliferative glomerulonephritis (GN) in 8 patients, pauci-immune crescentic GN or necrotizing vasculitis in 3 patients (with a mild to severe interstitial inflammation), and an isolated interstitial nephritis in 1 patient. C1q deposits were observed in the glomeruli (n=6), tubules (n=4) or renal arterioles (n=3) of 8 patients. All patients received corticosteroids, and 9 were also treated with immunosuppressants or apheresis. After a mean follow-up of 8.9 years, 6 patients had a preserved renal function, but 2 patients had developed stage 3-4 chronic kidney disease (CKD) and 4 patients had reached end-stage kidney disease (ESKD), among whom 1 had received a kidney transplant. Conclusion. Renal involvement of HUV can be responsible for severe AKI, CKD and ESKD. It is not always associated with circulating anti-C1q antibodies. Kidney biopsy shows mostly membrano-proliferative GN or crescentic GN, with frequent C1q deposits in the glomeruli, tubules or arterioles.

ACS Style

Alice Corthier; Marie Jachiet; Daniel Bertin; Aude Servais; Christelle Barbet; Adrien Bigot; Marie-Sylvie Doutre; Didier Bessis; Ancuta Bouffandeau; Olivier Moranne; Pierre-André Jarrot; Nathalie Bardin; Benjamin Terrier; Stephane Burtey; Xavier Puéchal; Laurent Daniel; Noémie Jourde-Chiche. Biopsy-Proven Kidney Involvement in Hypocomplementemic Urticarial Vasculitis. 2021, 1 .

AMA Style

Alice Corthier, Marie Jachiet, Daniel Bertin, Aude Servais, Christelle Barbet, Adrien Bigot, Marie-Sylvie Doutre, Didier Bessis, Ancuta Bouffandeau, Olivier Moranne, Pierre-André Jarrot, Nathalie Bardin, Benjamin Terrier, Stephane Burtey, Xavier Puéchal, Laurent Daniel, Noémie Jourde-Chiche. Biopsy-Proven Kidney Involvement in Hypocomplementemic Urticarial Vasculitis. . 2021; ():1.

Chicago/Turabian Style

Alice Corthier; Marie Jachiet; Daniel Bertin; Aude Servais; Christelle Barbet; Adrien Bigot; Marie-Sylvie Doutre; Didier Bessis; Ancuta Bouffandeau; Olivier Moranne; Pierre-André Jarrot; Nathalie Bardin; Benjamin Terrier; Stephane Burtey; Xavier Puéchal; Laurent Daniel; Noémie Jourde-Chiche. 2021. "Biopsy-Proven Kidney Involvement in Hypocomplementemic Urticarial Vasculitis." , no. : 1.

Journal article
Published: 14 April 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Background: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). The therapeutic strategy relies on kidney biopsy (KB) results. We tested whether urinary peptidome analysis could non-invasively differentiate active from non-active LN. Design: Urinary samples were collected from 93 patients (55 with active LN and 38 with non-active LN), forming a discovery (n = 42) and an independent validation (n = 51) cohort. Clinical characteristics were collected at inclusion and prospectively for 24 months. The urinary peptidome was analyzed by capillary-electrophoresis coupled to mass-spectrometry, comparing active LN to non-active LN, and assessing chronic lesions and response to therapy. The value of previously validated prognostic (CKD273) and differential diagnostic (LN172) signatures was evaluated. Results: Urinary peptides could not discriminate between active and non-active LN or predict early response to therapy. Tubulo-interstitial fibrosis was correlated to the CKD273. The LN172 score identified 92.5% of samples as LN. Few patients developed new-onset CKD. Conclusions: We validated the CKD273 and LN172 classifiers but did not identify a robust signature that could predict active LN and replace KB. The value of urinary peptidome to predict long-term CKD, or renal flares in SLE, remains to be evaluated.

ACS Style

Maxence Tailliar; Joost Schanstra; Tim Dierckx; Benjamin Breuil; Guillaume Hanouna; Nicolas Charles; Jean-Loup Bascands; Bertrand Dussol; Alain Vazi; Laurent Chiche; Justyna Siwy; Stanislas Faguer; Laurent Daniel; Eric Daugas; Noémie Jourde-Chiche; On Behalf Of The Groupe Coopératif Sur le Lupus Rénal (Gclr). Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine 2021, 10, 1690 .

AMA Style

Maxence Tailliar, Joost Schanstra, Tim Dierckx, Benjamin Breuil, Guillaume Hanouna, Nicolas Charles, Jean-Loup Bascands, Bertrand Dussol, Alain Vazi, Laurent Chiche, Justyna Siwy, Stanislas Faguer, Laurent Daniel, Eric Daugas, Noémie Jourde-Chiche, On Behalf Of The Groupe Coopératif Sur le Lupus Rénal (Gclr). Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study. Journal of Clinical Medicine. 2021; 10 (8):1690.

Chicago/Turabian Style

Maxence Tailliar; Joost Schanstra; Tim Dierckx; Benjamin Breuil; Guillaume Hanouna; Nicolas Charles; Jean-Loup Bascands; Bertrand Dussol; Alain Vazi; Laurent Chiche; Justyna Siwy; Stanislas Faguer; Laurent Daniel; Eric Daugas; Noémie Jourde-Chiche; On Behalf Of The Groupe Coopératif Sur le Lupus Rénal (Gclr). 2021. "Urinary Peptides as Potential Non-Invasive Biomarkers for Lupus Nephritis: Results of the Peptidu-LUP Study." Journal of Clinical Medicine 10, no. 8: 1690.

Preprint content
Published: 09 April 2021
Reads 0
Downloads 0

Background: Few data is available on the risk/benefit balance of native kidney biopsy (KB) in very elderly patients.Methods: Multicenter retrospective cohort study in the Aix-Marseille area: the results of KB and medical charts of all patients over 85 years biopsied between January 2010 and December 2018 were reviewed. Results: 104 patients were included. Median age was 87 years. Indications for KB were: acute kidney injury (AKI) in 69.2% of patients, nephrotic syndrome (NS) with AKI in 13.5%, NS without AKI in 12.5%, and proteinuria in 4.8%. Median serum creatinine was 262 mmol/L, 21% of patients required dialysis at the time of KB. Significant bleeding occurred in 7 (6.7%) patients, requiring blood cell transfusion in 4 (3.8%), and radiological embolization in 1 (1%). The most frequent pathological diagnoses were: non-diabetic glomerular diseases (29.8%, including pauci-immune crescentic glomerulonephritis in 9.6%), hypertensive nephropathy (27.9%), acute interstitial nephritis (16.3%), renal involvement of hematological malignancy (8.7%), and acute tubular necrosis (6.7%). After KB, 51 (49%) patients received a specific treatment: corticosteroids (41.3%), cyclophosphamide (6.7%), rituximab (6.7%), bortezomib (3.8%), other chemotherapies (3.8%). Median overall survival was 31 months. Median renal survival was higher in patients without AKI (p=0.007) or treated with corticosteroids (p=0.046). Dialysis-free survival censored for death was higher in patients without AKI (p=0.019), or treated (p=0.022), especially with corticosteroids (p=0.006).Conclusions: KB can reveal a diagnosis with therapeutic impact even in very elderly patients. Severe bleeding was not frequent in this cohort, but KB may have not been performed in more vulnerable patients.

ACS Style

Mathilde Fedi; Mickaël Bobot; Julia Torrents; Pierre Gobert; Eric Magnant; Yannick Knefati; David Verhelst; Gaëtan Lebrun; Valérie Masson; Philippe Giaime; Julien Santini; Stanislas Bataille; Philippe Brunet; Bertrand Dussol; Stéphane Burtey; Julien Mancini; Laurent Daniel; Noémie Jourde-Chiche. Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. 2021, 1 .

AMA Style

Mathilde Fedi, Mickaël Bobot, Julia Torrents, Pierre Gobert, Eric Magnant, Yannick Knefati, David Verhelst, Gaëtan Lebrun, Valérie Masson, Philippe Giaime, Julien Santini, Stanislas Bataille, Philippe Brunet, Bertrand Dussol, Stéphane Burtey, Julien Mancini, Laurent Daniel, Noémie Jourde-Chiche. Kidney biopsy in very elderly patients: indications, therapeutic impact and complications. . 2021; ():1.

Chicago/Turabian Style

Mathilde Fedi; Mickaël Bobot; Julia Torrents; Pierre Gobert; Eric Magnant; Yannick Knefati; David Verhelst; Gaëtan Lebrun; Valérie Masson; Philippe Giaime; Julien Santini; Stanislas Bataille; Philippe Brunet; Bertrand Dussol; Stéphane Burtey; Julien Mancini; Laurent Daniel; Noémie Jourde-Chiche. 2021. "Kidney biopsy in very elderly patients: indications, therapeutic impact and complications." , no. : 1.

Research article
Published: 01 April 2021 in Hypertension
Reads 0
Downloads 0

CD146 is an endothelial junctional adhesion molecule, which expression is increased in human glomerular diseases. However, the pathological significance of this overexpression remains unknown. Induction of glomerulonephritis in mice, by using nephrotoxic serum, showed that CD146 expression was highly induced within damaged glomeruli and was associated with renal inflammation and fibrosis. Interestingly, 2 weeks after glomerulonephritis induction, CD146 knockout mice showed preserved renal function as proteinuria and blood urea nitrogen levels were significantly lower compared with wild-type littermates. Furthermore, renal structure was considerably conserved, since crescents formation, tubular dilation, monocyte and lymphocyte infiltration, and interstitial renal fibrosis were highly reduced. Colocalization with markers for different types of glomerular cells showed that CD146 expression was mainly increased within the injured endothelium of the glomerular tuft. Consequently, we generated a new transgenic strain in which CD146 was specifically deleted in the vascular endothelium. Similarly to CD146 knockout, these mice showed preservation of renal structure and function after the induction of glomerulonephritis compared with wild-type animals. These data show that endothelial CD146 plays a major role in glomerulonephritis and may represent a novel therapeutic target to reduce glomerular damage and the progression of renal disease.

ACS Style

Ahmed Abed; Aurélie S. Leroyer; Panagiotis Kavvadas; Florence Authier; Richard Bachelier; Alexandrine Foucault-Bertaud; Nathalie Bardin; Clemens D. Cohen; Maja T. Lindenmeyer; Magali Genest; Ahmad Joshkon; Noémie Jourde-Chiche; Stéphane Burtey; Marcel Blot-Chabaud; Françoise Dignat-George; Christos E. Chadjichristos. Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. Hypertension 2021, 77, 1260 -1272.

AMA Style

Ahmed Abed, Aurélie S. Leroyer, Panagiotis Kavvadas, Florence Authier, Richard Bachelier, Alexandrine Foucault-Bertaud, Nathalie Bardin, Clemens D. Cohen, Maja T. Lindenmeyer, Magali Genest, Ahmad Joshkon, Noémie Jourde-Chiche, Stéphane Burtey, Marcel Blot-Chabaud, Françoise Dignat-George, Christos E. Chadjichristos. Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. Hypertension. 2021; 77 (4):1260-1272.

Chicago/Turabian Style

Ahmed Abed; Aurélie S. Leroyer; Panagiotis Kavvadas; Florence Authier; Richard Bachelier; Alexandrine Foucault-Bertaud; Nathalie Bardin; Clemens D. Cohen; Maja T. Lindenmeyer; Magali Genest; Ahmad Joshkon; Noémie Jourde-Chiche; Stéphane Burtey; Marcel Blot-Chabaud; Françoise Dignat-George; Christos E. Chadjichristos. 2021. "Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice." Hypertension 77, no. 4: 1260-1272.

Letter to the editor
Published: 08 November 2020 in Arthritis & Rheumatology
Reads 0
Downloads 0

We read with interest the study by Posada et al. (1) evaluating the therapeutic effects of RSLV‐132 (a new RNase compound) in patients with primary Sjogren syndrome (pSS). At first glance, one may be surprised by the enthusiastic conclusion of authors in spite of a biological effect opposite to what was expected, namely an increased expression of interferon (IFN)‐stimulated genes (ISG), while pSS is considered as an acquired interferonopathy. However, therapeutic trials are also a unique opportunity to learn about the pathogenesis of such complex condition. Indeed, this study showed a significant improvement of fatigue (measured by various validated scales) in treated patients, surprisingly correlated with the increased expression of ISG.

ACS Style

Laurent Chiche; Noémie Jourde‐Chiche; Divi Cornec. Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. Arthritis & Rheumatology 2020, 73, 717 -718.

AMA Style

Laurent Chiche, Noémie Jourde‐Chiche, Divi Cornec. Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al. Arthritis & Rheumatology. 2020; 73 (4):717-718.

Chicago/Turabian Style

Laurent Chiche; Noémie Jourde‐Chiche; Divi Cornec. 2020. "Should the Biopsychosocial Model Be Considered in Systemic Autoimmune Diseases? Comment on the Article by Posada et al." Arthritis & Rheumatology 73, no. 4: 717-718.

Comment
Published: 01 October 2020 in Clinical Kidney Journal
Reads 0
Downloads 0

Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease, related to severe acute respiratory syndrome coronavirus 2 infection. Few data are available in patients with end-stage renal disease (ESRD). Methods We conducted an observational cohort study of COVID-19 patients at 11 dialysis centres in two distinct districts of France to examine the epidemiological and clinical characteristics of COVID-19 in this population, and to determine risk factors of disease severity (defined as a composite outcome including intensive care unit admission or death) and mortality. Results Among the 2336 patients enrolled, 5.5% had confirmed COVID-19 diagnosis. Of the 122 patients with a follow-up superior to 28 days, 37% reached the composite outcome and 28% died. Multivariate analysis showed that oxygen therapy on diagnosis and a decrease in lymphocyte count were independent risk factors associated with disease severity and with mortality. Chronic use of angiotensin II receptor blockers (ARBs) (18% of patients) was associated with a protective effect on mortality. Treatment with azithromycin and hydroxychloroquine (AZT/HCQ) (46% of patients) were not associated with the composite outcome and with death in univariate and multivariate analyses. Conclusions COVID-19 is a severe disease with poor prognosis in patients with ESRD. Usual treatment with ARBs seems to be protective of critical evolution and mortality. There is no evidence of clinical benefit with the combination of AZT/HCQ.

ACS Style

Guillaume Lano; Antoine Braconnier; Stanislas Bataille; Guilhem Cavaille; Julie Moussi-Frances; Bertrand Gondouin; Pascal Bindi; Magued Nakhla; Janette Mansour; Pascale Halin; Bénédicte Levy; Eric Canivet; Khaled Gaha; Isabelle Kazes; Natacha Noel; Alain Wynckel; Alexandre Debrumetz; Noemie Jourde-Chiche; Valerie Moal; Romain Vial; Violaine Scarfoglière; Mickael Bobot; Marion Gully; Tristan Legris; Marion Pelletier; Marion Sallee; Stephane Burtey; Philippe Brunet; Thomas Robert; Philippe Rieu. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. Clinical Kidney Journal 2020, 13, 878 -888.

AMA Style

Guillaume Lano, Antoine Braconnier, Stanislas Bataille, Guilhem Cavaille, Julie Moussi-Frances, Bertrand Gondouin, Pascal Bindi, Magued Nakhla, Janette Mansour, Pascale Halin, Bénédicte Levy, Eric Canivet, Khaled Gaha, Isabelle Kazes, Natacha Noel, Alain Wynckel, Alexandre Debrumetz, Noemie Jourde-Chiche, Valerie Moal, Romain Vial, Violaine Scarfoglière, Mickael Bobot, Marion Gully, Tristan Legris, Marion Pelletier, Marion Sallee, Stephane Burtey, Philippe Brunet, Thomas Robert, Philippe Rieu. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort. Clinical Kidney Journal. 2020; 13 (5):878-888.

Chicago/Turabian Style

Guillaume Lano; Antoine Braconnier; Stanislas Bataille; Guilhem Cavaille; Julie Moussi-Frances; Bertrand Gondouin; Pascal Bindi; Magued Nakhla; Janette Mansour; Pascale Halin; Bénédicte Levy; Eric Canivet; Khaled Gaha; Isabelle Kazes; Natacha Noel; Alain Wynckel; Alexandre Debrumetz; Noemie Jourde-Chiche; Valerie Moal; Romain Vial; Violaine Scarfoglière; Mickael Bobot; Marion Gully; Tristan Legris; Marion Pelletier; Marion Sallee; Stephane Burtey; Philippe Brunet; Thomas Robert; Philippe Rieu. 2020. "Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort." Clinical Kidney Journal 13, no. 5: 878-888.

Journal article
Published: 17 September 2020 in Nephrology Dialysis Transplantation
Reads 0
Downloads 0

Background Immune checkpoints inhibitors have transformed the prognosis of advanced melanoma but are associated with immune-related adverse events (irAEs). We evaluated the incidence, risk factors and causes of acute kidney injury (AKI) in a monocentric real-life cohort of patients treated with anti-programmed death receptor-1 (anti-PD1) antibodies for advanced melanoma. Methods Retrospective collection of medical charts and comprehensive analysis of lab results from patients treated with nivolumab or pembrolizumab for advanced melanoma between 2014 and 2018 was carried out. AKI was defined by Kidney Disease Improving Global Outcomes criteria, and causes were determined by chart review. Overall survival, survival without AKI and impact of AKI on survival were analysed. Risk factors for death and for AKI were identified. Results Two hundred and thirty-nine patients were included. Forty-one (17%) had at least one episode of AKI. Independent risk factors for AKI were treatment with renin–angiotensin–aldosterone system inhibitors (RAASi), pre-existing chronic kidney disease (CKD) and cumulated doses of anti-PD1. The main cause of AKI was prerenal, and only eight patients (3.3%) developed acute interstitial nephritis; 8% of patients developed CKD. The median overall survival was 13.4 months and was not affected by AKI. In multivariate analysis, the overall mortality was lower in overweight and obese patients and higher in patients treated with proton-pump inhibitors (PPI) or corticosteroids. Conclusions AKI is common in patients treated with anti-PD1 for advanced melanoma but is mostly prerenal and favoured by the use of RAASi; renal irAE is rare. PPI and corticosteroids were associated with poor survival in this population, while overweight/obesity was protective.

ACS Style

Claire Stein; Stéphane Burtey; Julien Mancini; Marion Pelletier; Marion Sallée; Philippe Brunet; Philippe Berbis; Jean Jacques Grob; Stéphane Honoré; Caroline Gaudy; Noémie Jourde-Chiche. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrology Dialysis Transplantation 2020, 36, 1664 -1674.

AMA Style

Claire Stein, Stéphane Burtey, Julien Mancini, Marion Pelletier, Marion Sallée, Philippe Brunet, Philippe Berbis, Jean Jacques Grob, Stéphane Honoré, Caroline Gaudy, Noémie Jourde-Chiche. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrology Dialysis Transplantation. 2020; 36 (9):1664-1674.

Chicago/Turabian Style

Claire Stein; Stéphane Burtey; Julien Mancini; Marion Pelletier; Marion Sallée; Philippe Brunet; Philippe Berbis; Jean Jacques Grob; Stéphane Honoré; Caroline Gaudy; Noémie Jourde-Chiche. 2020. "Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort." Nephrology Dialysis Transplantation 36, no. 9: 1664-1674.

Conference abstract
Published: 16 September 2020 in Néphrologie & Thérapeutique
Reads 0
Downloads 0

Les patients en hémodialyse chronique (HDC) ne peuvent rester confinés (séances de dialyse), et sont à risque de formes graves de COVID-19 (comorbidités, immunodépression). Leurs soignants sont également exposés. Objectif principal : prévalence à M0 de la séroconversion SARS-CoV-2 dans une cohorte de patients HDC. Objectifs secondaires : (1) prévalence à M0 de la séroconversion chez les soignants en dialyse ; (2) proportion de COVID-19 asymptomatiques, et association avec les caractéristiques cliniques et comorbidités ; (3) prévalence de la séroconversion à M0 chez les participants ayant présenté une COVID-19 documentée ; (4) cinétique de la séroconversion et évolution de l’épidémie (2e test à M3) ; (5) valeur prédictive d’une séroconversion à M0 sur le risque de COVID-19 symptomatique à M6 ; (7) performances diagnostiques intrinsèques du test rapide (vs gold standard sérologique). Étude de cohorte multicentrique (NCT04420338), 4 centres de dialyse d’Aix-Marseille, tri à l’arrivée à chaque séance (signes cliniques de COVID-19) depuis début mars 2020 (arrivée de l’épidémie dans la région). Critères d’inclusion : âge ≥ 18 ans, patient HDC ou soignant de dialyse. Critères de non-inclusion : personne protégée. Déroulement : inclusion synchronisée des participants en juin 2020. Recueil des données cliniques et tests sérologiques rapides Biosynex à M0 et M3 (patients et soignants). Sérum prélevé à M0 et M3 (patients uniquement) pour la sérologie gold standard ultérieure (ELISA et séro-neutralisation). Suivi jusqu’à M6 (survenue d’une COVID-19 ?). Nombre de participants : 800 (561 patients, 239 soignants). Prévalence de la séroconversion à M0 chez les patients HDC et leurs soignants, prévalence des formes asymptomatiques, et association avec les caractéristiques cliniques et comorbidités. Étude menée dans une région moyennement touchée par la pandémie, qui fera avancer les connaissances et l’organisation des soins en dialyse.

ACS Style

T. Robert; S. Bataille; P. Sebahoun; R. Vial; M. Bobot; N. Resseguier; G. Lebrun; P. Brunet; N. Jourde-Chiche. Étude SéroCOVIDial : évaluation de la séroconversion SARS-CoV-2 chez les patients hémodialysés chroniques et leurs soignants, étude de cohorte. Néphrologie & Thérapeutique 2020, 16, 327 -327.

AMA Style

T. Robert, S. Bataille, P. Sebahoun, R. Vial, M. Bobot, N. Resseguier, G. Lebrun, P. Brunet, N. Jourde-Chiche. Étude SéroCOVIDial : évaluation de la séroconversion SARS-CoV-2 chez les patients hémodialysés chroniques et leurs soignants, étude de cohorte. Néphrologie & Thérapeutique. 2020; 16 (5):327-327.

Chicago/Turabian Style

T. Robert; S. Bataille; P. Sebahoun; R. Vial; M. Bobot; N. Resseguier; G. Lebrun; P. Brunet; N. Jourde-Chiche. 2020. "Étude SéroCOVIDial : évaluation de la séroconversion SARS-CoV-2 chez les patients hémodialysés chroniques et leurs soignants, étude de cohorte." Néphrologie & Thérapeutique 16, no. 5: 327-327.

Journal article
Published: 15 August 2020 in The Journal of Rheumatology
Reads 0
Downloads 0

Objective Immunoglobulin A vasculitis (IgAV) and nephropathy (IgAN) share common immunological mechanisms. Liver cirrhosis is well known to be associated with IgAN. Here, we aimed to describe the presentation and outcome of IgAV patients with underlying cirrhosis. Methods We conducted a French nationwide retrospective study of adult patients presenting with both IgAV and cirrhosis. Baseline characteristics were compared to those of the 260 patients included in the French nationwide IgAV registry (IGAVAS). Results Twenty patients were included, and 7 (35%) were female. The mean ± SD age was 62.7 ± 11 years. At baseline, compared with IGAVAS patients, patients with underlying cirrhosis were older (62.7 ± 11 vs 50.1 ± 18, P < 0.01) and displayed more constitutional symptoms (weight loss 25% vs 8%, P = 0.03). Patients with underlying cirrhosis were also more likely to exhibit elevated serum IgA levels (5.6 g/L vs 3.6 g/L, P = 0.02). Cirrhosis and IgAV were diagnosed simultaneously in 12 patients (60%). Cirrhosis was mainly related to alcohol intake (n = 15, 75%), followed by nonalcoholic steato-hepatitis (n = 2), chronic viral hepatitis (n = 1), hemochromatosis (n = 1), and autoimmune hepatitis (n = 1). During follow-up with a median of 17 months (IQR 12–84), 10/13 (77%) exhibited IgAV remission at Month 3. One patient presented a minor relapse. Six patients died, but no deaths were related to IgAV. Conclusion We report the first case series of IgAV patients with underlining cirrhosis, to our knowledge, which was mainly alcohol related. The liver disease did not seem to affect baseline vasculitis characteristics. Physicians should investigate the existence of liver cirrhosis at IgAV diagnosis, especially in the context of alcohol abuse.

ACS Style

Ines Elhani; Evangéline Pillebout; Benjamin Terrier; Antoine Hankard; François Vrtovsnik; Noémie Jourde-Chiche; Sophie Greillier; Matthieu Groh; Nabil Belfeki; Adrien Bigot; Hubert de Boysson; Georges-Philippe Pageaux; Loïc Raffray; Geoffrey Urbanski; Isabelle Ollivier; Francois Maillot; Achille Aouba; Alexandra Audemard-Verger; Alexandra Audemard-Verger on behalf of the French Vasculitis Study Group (FVSG) and the HSPrognosis Group. IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. The Journal of Rheumatology 2020, 48, 735 -740.

AMA Style

Ines Elhani, Evangéline Pillebout, Benjamin Terrier, Antoine Hankard, François Vrtovsnik, Noémie Jourde-Chiche, Sophie Greillier, Matthieu Groh, Nabil Belfeki, Adrien Bigot, Hubert de Boysson, Georges-Philippe Pageaux, Loïc Raffray, Geoffrey Urbanski, Isabelle Ollivier, Francois Maillot, Achille Aouba, Alexandra Audemard-Verger, Alexandra Audemard-Verger on behalf of the French Vasculitis Study Group (FVSG) and the HSPrognosis Group. IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients. The Journal of Rheumatology. 2020; 48 (5):735-740.

Chicago/Turabian Style

Ines Elhani; Evangéline Pillebout; Benjamin Terrier; Antoine Hankard; François Vrtovsnik; Noémie Jourde-Chiche; Sophie Greillier; Matthieu Groh; Nabil Belfeki; Adrien Bigot; Hubert de Boysson; Georges-Philippe Pageaux; Loïc Raffray; Geoffrey Urbanski; Isabelle Ollivier; Francois Maillot; Achille Aouba; Alexandra Audemard-Verger; Alexandra Audemard-Verger on behalf of the French Vasculitis Study Group (FVSG) and the HSPrognosis Group. 2020. "IgA Vasculitis With Underlying Liver Cirrhosis: A French Nationwide Case Series of 20 Patients." The Journal of Rheumatology 48, no. 5: 735-740.

Journal article
Published: 09 July 2020 in BMC Nephrology
Reads 0
Downloads 0

The seroprevalence of human Parvovirus B19 (PVB19) is 70–85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy. Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017–2018. The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis. PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

ACS Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noémie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. BMC Nephrology 2020, 21, 1 -8.

AMA Style

Maëlis Kauffmann, Mickaël Bobot, Laurent Daniel, Julia Torrents, Yannick Knefati, Olivier Moranne, Stéphane Burtey, Christine Zandotti, Noémie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. BMC Nephrology. 2020; 21 (1):1-8.

Chicago/Turabian Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noémie Jourde-Chiche. 2020. "Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy." BMC Nephrology 21, no. 1: 1-8.

Preprint content
Published: 25 June 2020
Reads 0
Downloads 0

BACKGROUND: The seroprevalence of human Parvovirus B19 (PVB19) is 70-85 % in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy.METHODS: Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018.RESULTS: The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis. CONCLUSION: PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

ACS Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noemie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. 2020, 1 .

AMA Style

Maëlis Kauffmann, Mickaël Bobot, Laurent Daniel, Julia Torrents, Yannick Knefati, Olivier Moranne, Stéphane Burtey, Christine Zandotti, Noemie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. . 2020; ():1.

Chicago/Turabian Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noemie Jourde-Chiche. 2020. "Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy." , no. : 1.

Journal article
Published: 01 June 2020 in Kidney International
Reads 0
Downloads 0

Protein-bound uremic toxins (PBUTs) accumulate in chronic kidney disease (CKD) and are poorly removed by dialysis. Gryp et al. demonstrated that fecal bacteria from patients with CKD do not produce more PBUTs than do those from healthy controls and that the accumulation of PBUTs, as CKD progresses, is mainly due to their reduced renal elimination by glomerular filtration and tubular secretion. This work underlines the importance of studying the metabolism of PBUTs along the diet-gut-liver-kidney axis.

ACS Style

Noémie Jourde-Chiche; Stéphane Burtey. Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. Kidney International 2020, 97, 1102 -1104.

AMA Style

Noémie Jourde-Chiche, Stéphane Burtey. Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis. Kidney International. 2020; 97 (6):1102-1104.

Chicago/Turabian Style

Noémie Jourde-Chiche; Stéphane Burtey. 2020. "Accumulation of protein-bound uremic toxins: the kidney remains the leading culprit in the gut-liver-kidney axis." Kidney International 97, no. 6: 1102-1104.

Journal article
Published: 23 May 2020 in Rheumatology
Reads 0
Downloads 0
ACS Style

Pierre Charles; Agnès Dechartres; Benjamin Terrier; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Luc Mouthon; Loïc Guillevin; for the French Vasculitis Study Group. Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology 2020, 59, 3119 -3119.

AMA Style

Pierre Charles, Agnès Dechartres, Benjamin Terrier, Pascal Cohen, Stanislas Faguer, Antoine Huart, Mohamed Hamidou, Christian Agard, Bernard Bonnotte, Maxime Samson, Alexandre Karras, Noémie Jourde-Chiche, François Lifermann, Pierre Gobert, Catherine Hanrotel-Saliou, Pascal Godmer, Nicolas Martin-Silva, Grégory Pugnet, Marie Matignon, Olivier Aumaitre, Jean-François Viallard, François Maurier, Nadine Meaux-Ruault, Sophie Rivière, Jean Sibilia, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, for the French Vasculitis Study Group. Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology. 2020; 59 (10):3119-3119.

Chicago/Turabian Style

Pierre Charles; Agnès Dechartres; Benjamin Terrier; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Luc Mouthon; Loïc Guillevin; for the French Vasculitis Study Group. 2020. "Corrigendum to: Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis." Rheumatology 59, no. 10: 3119-3119.

Journal article
Published: 22 May 2020 in Clinical Journal of the American Society of Nephrology
Reads 0
Downloads 0

Background and objectivesMalaria, a potentially life-threatening disease, is the most prevalent endemic infectious disease worldwide. In the modern era, the spectrum of glomerular involvement observed in patients after malarial infections remains poorly described.Design, setting, participants, & measurementsWe therefore performed a retrospective multicenter study to assess the clinical, biologic, pathologic, and therapeutic characteristics of patients with glomerular disease demonstrated by kidney biopsy in France within 3 months of an acute malaria episode.ResultsWe identified 23 patients (12 men), all but 1 of African ancestry and including 10 patients with concomitant HIV infection. All of the imported cases were in French citizens living in France who had recently traveled back to France from an endemic area and developed malaria after their return to France. Eleven patients had to be admitted to an intensive care unit at presentation. Plasmodium falciparum was detected in 22 patients, and Plasmodium malariae was detected in 1 patient. Kidney biopsy was performed after the successful treatment of malaria, a mean of 24 days after initial presentation. At this time, all patients displayed AKI, requiring KRT in 12 patients. Nephrotic syndrome was diagnosed in 17 patients. Pathologic findings included FSGS in 21 patients and minimal change nephrotic syndrome in 2 patients. Among patients with FSGS, 18 had collapsing glomerulopathy (including 9 patients with HIV-associated nephropathy). In four patients, immunohistochemistry with an antibody targeting P. falciparum histidine-rich protein-2 demonstrated the presence of the malaria antigen in tubular cells but not in podocytes or parietal epithelial cells. An analysis of the apoL1 risk genotype showed that high-risk variants were present in all seven patients tested. After a mean follow-up of 23 months, eight patients required KRT (kidney transplantation in two patients), and mean eGFR for the other patients was 51 ml/min per 1.73 m2.ConclusionsIn patients of African ancestry, imported Plasmodium infection may be a new causal factor for secondary FSGS, particularly for collapsing glomerulopathy variants in an APOL1 high-risk variant background.

ACS Style

Ariane Amoura; Anissa Moktefi; Matthieu Halfon; Alexandre Karras; Cédric Rafat; Jean-Baptiste Gibier; Patrick J. Gleeson; Aude Servais; Nicolas Argy; Pascale Maillé; Xavier Belenfant; Victor Gueutin; Alexia Delpierre; Leila Tricot; Khalil El Karoui; Noémie Jourde-Chiche; Sandrine Houze; Dil Sahali; Vincent Audard. Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology 2020, 15, 964 -972.

AMA Style

Ariane Amoura, Anissa Moktefi, Matthieu Halfon, Alexandre Karras, Cédric Rafat, Jean-Baptiste Gibier, Patrick J. Gleeson, Aude Servais, Nicolas Argy, Pascale Maillé, Xavier Belenfant, Victor Gueutin, Alexia Delpierre, Leila Tricot, Khalil El Karoui, Noémie Jourde-Chiche, Sandrine Houze, Dil Sahali, Vincent Audard. Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology. 2020; 15 (7):964-972.

Chicago/Turabian Style

Ariane Amoura; Anissa Moktefi; Matthieu Halfon; Alexandre Karras; Cédric Rafat; Jean-Baptiste Gibier; Patrick J. Gleeson; Aude Servais; Nicolas Argy; Pascale Maillé; Xavier Belenfant; Victor Gueutin; Alexia Delpierre; Leila Tricot; Khalil El Karoui; Noémie Jourde-Chiche; Sandrine Houze; Dil Sahali; Vincent Audard. 2020. "Malaria, Collapsing Glomerulopathy, and Focal and Segmental Glomerulosclerosis." Clinical Journal of the American Society of Nephrology 15, no. 7: 964-972.

Research letter
Published: 20 April 2020 in Kidney International Reports
Reads 0
Downloads 0

Edema is the main symptom of nephrotic syndrome associated to minimal change disease (MCD). Besides the increase in glomerular permeability, possibly induced by a circulating permeability factor,1Maas R.J. Deegens J.K. Wetzels J.F. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.Nephrol Dial Transplant. 2014; 1: 2207-2216Crossref Scopus (47) Google Scholar an increase in systemic vascular permeability could participate in the constitution of edema.

ACS Style

Florence Daviet; Muriel G. Blin; Karim Fallague; Richard Bachelier; Manon Laforêt; Manon Carré; Stéphane Poitevin; Françoise Dignat-George; Marcel Blot-Chabaud; Nathalie Bardin; Stéphane Burtey; Noémie Jourde-Chiche; Aurélie S. Leroyer. Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. Kidney International Reports 2020, 5, 1071 -1075.

AMA Style

Florence Daviet, Muriel G. Blin, Karim Fallague, Richard Bachelier, Manon Laforêt, Manon Carré, Stéphane Poitevin, Françoise Dignat-George, Marcel Blot-Chabaud, Nathalie Bardin, Stéphane Burtey, Noémie Jourde-Chiche, Aurélie S. Leroyer. Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. Kidney International Reports. 2020; 5 (7):1071-1075.

Chicago/Turabian Style

Florence Daviet; Muriel G. Blin; Karim Fallague; Richard Bachelier; Manon Laforêt; Manon Carré; Stéphane Poitevin; Françoise Dignat-George; Marcel Blot-Chabaud; Nathalie Bardin; Stéphane Burtey; Noémie Jourde-Chiche; Aurélie S. Leroyer. 2020. "Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium." Kidney International Reports 5, no. 7: 1071-1075.

Journal article
Published: 31 March 2020 in Journal of Clinical Medicine
Reads 0
Downloads 0

Reliable non-invasive biomarkers are needed to assess disease activity and prognosis in patients with systemic lupus erythematosus (SLE). Glycoprotein acetylation (GlycA), a novel biomarker for chronic inflammation, has been reported to be increased in several inflammatory diseases. We investigated the relevance of serum GlycA in SLE patients exhibiting various levels of activity and severity, especially with regards to renal involvement. Serum GlycA was measured by nuclear magnetic resonance spectroscopy in samples from well characterized SLE patients and from both healthy controls and patients with other kidney diseases (KD). Disease activity was evaluated using the Systemic Lupus Erythematosus Activity Index 2000 (SLEDAI-2K). Renal severity was assessed by kidney biopsy. Serum GlycA was elevated in active (n = 105) compared to quiescent SLE patients (n = 39, p < 10-6), healthy controls (n = 20, p = 0.009) and KD controls (n = 21, p = 0.04), despite a more severely altered renal function in the latter. GlycA level was correlated to disease activity (SLEDAI-2K, ρ = 0.37, p < 10-4), Creactive protein, neutrophil count, triglyceride levels, proteinuria and inversely to serum albumin. In patients with biopsy-proven lupus nephritis (LN), GlycA levels were higher in proliferative (n = 26) than non-proliferative LN (n = 10) in univariate analysis (p = 0.04), and was shown to predict proliferative LN independently of renal parameters, immunological activity, neutrophil count and daily corticosteroid dosage by multivariate analysis (p < 5 × 10-3 for all models). In LN patients with repeated longitudinal GlycA measurement (n = 11), GlycA varied over time and seemed to peak at the time of the flare. GlycA, as a summary measure for different inflammatory processes, could be a valuable biomarker of disease activity in patients with SLE, and a non-invasive biomarker of pathological severity in the context of LN.

ACS Style

Tim Dierckx; Laurent Chiche; Laurent Daniel; Bernard Lauwerys; Johan Van Weyenbergh; Noémie Jourde-Chiche. Serum GlycA Level is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. Journal of Clinical Medicine 2020, 9, 970 .

AMA Style

Tim Dierckx, Laurent Chiche, Laurent Daniel, Bernard Lauwerys, Johan Van Weyenbergh, Noémie Jourde-Chiche. Serum GlycA Level is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity. Journal of Clinical Medicine. 2020; 9 (4):970.

Chicago/Turabian Style

Tim Dierckx; Laurent Chiche; Laurent Daniel; Bernard Lauwerys; Johan Van Weyenbergh; Noémie Jourde-Chiche. 2020. "Serum GlycA Level is Elevated in Active Systemic Lupus Erythematosus and Correlates to Disease Activity and Lupus Nephritis Severity." Journal of Clinical Medicine 9, no. 4: 970.

Journal article
Published: 09 March 2020 in Rheumatology
Reads 0
Downloads 0

Objective The randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12. Methods MAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free survival rates in each arm as primary end points. Exploratory subgroup analyses were run according to CYC or rituximab induction and newly diagnosed or relapsing AAV. Results At M3, M6, M9 and M12, respectively, among the 161 patients included, 79/80 (98.8%), 76/80 (95%), 74/80 (92.5%) and 73/80 (91.3%) from D0, and 80/81 (98.8%), 78/81 (96.3%), 76/81 (93.8%) and 76/81 (93.8%) from D0+D14 groups were alive and relapse-free. No between-group differences were observed. Results were not affected by CYC or rituximab induction, or newly diagnosed or relapsing AAV. Conclusions We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse-free rate. Nevertheless, results at M12 may also have been influenced by the rituximab-infusion strategies for both groups.

ACS Style

Pierre Charles; Agnès Dechartres; Benjamin Terrier; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Luc Mouthon; Loïc Guillevin; for the French Vasculitis Study Group. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology 2020, 59, 2970 -2975.

AMA Style

Pierre Charles, Agnès Dechartres, Benjamin Terrier, Pascal Cohen, Stanislas Faguer, Antoine Huart, Mohamed Hamidou, Christian Agard, Bernard Bonnotte, Maxime Samson, Alexandre Karras, Noémie Jourde-Chiche, François Lifermann, Pierre Gobert, Catherine Hanrotel-Saliou, Pascal Godmer, Nicolas Martin-Silva, Grégory Pugnet, Marie Matignon, Olivier Aumaitre, Jean-François Viallard, François Maurier, Nadine Meaux-Ruault, Sophie Rivière, Jean Sibilia, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, for the French Vasculitis Study Group. Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. Rheumatology. 2020; 59 (10):2970-2975.

Chicago/Turabian Style

Pierre Charles; Agnès Dechartres; Benjamin Terrier; Pascal Cohen; Stanislas Faguer; Antoine Huart; Mohamed Hamidou; Christian Agard; Bernard Bonnotte; Maxime Samson; Alexandre Karras; Noémie Jourde-Chiche; François Lifermann; Pierre Gobert; Catherine Hanrotel-Saliou; Pascal Godmer; Nicolas Martin-Silva; Grégory Pugnet; Marie Matignon; Olivier Aumaitre; Jean-François Viallard; François Maurier; Nadine Meaux-Ruault; Sophie Rivière; Jean Sibilia; Xavier Puéchal; Luc Mouthon; Loïc Guillevin; for the French Vasculitis Study Group. 2020. "Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis." Rheumatology 59, no. 10: 2970-2975.

Preprint content
Published: 26 February 2020
Reads 0
Downloads 0

BACKGROUND: The seroprevalence of human Parvovirus B19 (PVB19) is 70-85 % in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy.METHODS: Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018.RESULTS: The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis. CONCLUSION: PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

ACS Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noemie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. 2020, 1 .

AMA Style

Maëlis Kauffmann, Mickaël Bobot, Laurent Daniel, Julia Torrents, Yannick Knefati, Olivier Moranne, Stéphane Burtey, Christine Zandotti, Noemie Jourde-Chiche. Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy. . 2020; ():1.

Chicago/Turabian Style

Maëlis Kauffmann; Mickaël Bobot; Laurent Daniel; Julia Torrents; Yannick Knefati; Olivier Moranne; Stéphane Burtey; Christine Zandotti; Noemie Jourde-Chiche. 2020. "Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy." , no. : 1.